Mineralys Therapeutics (MLYS) Competitors $14.98 +0.50 (+3.42%) As of 02:53 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock MLYS vs. RARE, AAPG, MRUS, ACLX, SWTX, RNA, ACAD, SRRK, VKTX, and PTGXShould you be buying Mineralys Therapeutics stock or one of its competitors? The main competitors of Mineralys Therapeutics include Ultragenyx Pharmaceutical (RARE), Ascentage Pharma Group International (AAPG), Merus (MRUS), Arcellx (ACLX), SpringWorks Therapeutics (SWTX), Avidity Biosciences (RNA), ACADIA Pharmaceuticals (ACAD), Scholar Rock (SRRK), Viking Therapeutics (VKTX), and Protagonist Therapeutics (PTGX). These companies are all part of the "pharmaceutical products" industry. Mineralys Therapeutics vs. Its Competitors Ultragenyx Pharmaceutical Ascentage Pharma Group International Merus Arcellx SpringWorks Therapeutics Avidity Biosciences ACADIA Pharmaceuticals Scholar Rock Viking Therapeutics Protagonist Therapeutics Mineralys Therapeutics (NASDAQ:MLYS) and Ultragenyx Pharmaceutical (NASDAQ:RARE) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, earnings, dividends, profitability and analyst recommendations. Which has better earnings & valuation, MLYS or RARE? Mineralys Therapeutics has higher earnings, but lower revenue than Ultragenyx Pharmaceutical. Ultragenyx Pharmaceutical is trading at a lower price-to-earnings ratio than Mineralys Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMineralys TherapeuticsN/AN/A-$177.81M-$3.73-4.02Ultragenyx Pharmaceutical$560.23M4.93-$569.18M-$5.88-4.97 Is MLYS or RARE more profitable? Mineralys Therapeutics has a net margin of 0.00% compared to Ultragenyx Pharmaceutical's net margin of -93.04%. Mineralys Therapeutics' return on equity of -71.15% beat Ultragenyx Pharmaceutical's return on equity.Company Net Margins Return on Equity Return on Assets Mineralys TherapeuticsN/A -71.15% -65.71% Ultragenyx Pharmaceutical -93.04%-186.49%-36.81% Does the media refer more to MLYS or RARE? In the previous week, Ultragenyx Pharmaceutical had 37 more articles in the media than Mineralys Therapeutics. MarketBeat recorded 38 mentions for Ultragenyx Pharmaceutical and 1 mentions for Mineralys Therapeutics. Mineralys Therapeutics' average media sentiment score of 1.32 beat Ultragenyx Pharmaceutical's score of 0.09 indicating that Mineralys Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Mineralys Therapeutics Positive Ultragenyx Pharmaceutical Neutral Do analysts recommend MLYS or RARE? Mineralys Therapeutics presently has a consensus target price of $32.25, suggesting a potential upside of 115.22%. Ultragenyx Pharmaceutical has a consensus target price of $83.64, suggesting a potential upside of 186.39%. Given Ultragenyx Pharmaceutical's stronger consensus rating and higher probable upside, analysts clearly believe Ultragenyx Pharmaceutical is more favorable than Mineralys Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mineralys Therapeutics 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75Ultragenyx Pharmaceutical 0 Sell rating(s) 1 Hold rating(s) 13 Buy rating(s) 0 Strong Buy rating(s) 2.93 Which has more risk and volatility, MLYS or RARE? Mineralys Therapeutics has a beta of -0.3, indicating that its share price is 130% less volatile than the S&P 500. Comparatively, Ultragenyx Pharmaceutical has a beta of 0.26, indicating that its share price is 74% less volatile than the S&P 500. Do insiders & institutionals hold more shares of MLYS or RARE? 84.5% of Mineralys Therapeutics shares are held by institutional investors. Comparatively, 97.7% of Ultragenyx Pharmaceutical shares are held by institutional investors. 33.2% of Mineralys Therapeutics shares are held by insiders. Comparatively, 5.5% of Ultragenyx Pharmaceutical shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. SummaryUltragenyx Pharmaceutical beats Mineralys Therapeutics on 8 of the 15 factors compared between the two stocks. Get Mineralys Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MLYS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MLYS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MLYS vs. The Competition Export to ExcelMetricMineralys TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$977.83M$2.96B$5.54B$9.13BDividend YieldN/A2.43%5.06%4.01%P/E Ratio-4.0221.2228.2819.58Price / SalesN/A186.65373.3579.96Price / CashN/A41.0524.7227.50Price / Book3.907.728.265.55Net Income-$177.81M-$55.05M$3.19B$252.28M7 Day Performance10.75%12.50%5.27%2.99%1 Month Performance4.64%13.41%9.19%11.65%1 Year Performance3.49%4.02%30.12%17.15% Mineralys Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MLYSMineralys Therapeutics2.3555 of 5 stars$14.99+3.4%$32.25+115.2%+0.1%$977.83MN/A-4.0228Positive NewsGap DownRAREUltragenyx Pharmaceutical4.4048 of 5 stars$39.61-0.8%$87.00+119.6%-34.6%$3.77B$560.23M-6.741,294Trending NewsAnalyst ForecastAnalyst RevisionGap DownAAPGAscentage Pharma Group InternationalN/A$42.04-1.9%N/AN/A$3.73B$134.35M0.00600News CoverageGap DownMRUSMerus1.916 of 5 stars$52.58-2.3%$84.64+61.0%-4.8%$3.73B$36.13M-12.8937Analyst UpgradeInsider TradeACLXArcellx2.561 of 5 stars$65.55-2.4%$111.23+69.7%+10.5%$3.70B$107.94M-21.9280Positive NewsSWTXSpringWorks Therapeutics1.5801 of 5 stars$46.99flat$52.57+11.9%N/A$3.54B$191.59M-13.78230Positive NewsRNAAvidity Biosciences2.1854 of 5 stars$28.80-1.3%$65.59+127.7%-29.8%$3.52B$10.90M-9.60190Analyst ForecastGap UpACADACADIA Pharmaceuticals4.705 of 5 stars$20.88-0.3%$27.88+33.5%+18.1%$3.51B$957.80M15.24510Positive NewsAnalyst RevisionSRRKScholar Rock3.7289 of 5 stars$35.48-1.4%$42.67+20.3%+311.4%$3.42B$33.19M-14.02140VKTXViking Therapeutics4.5754 of 5 stars$27.51-2.4%$87.15+216.8%-45.6%$3.17BN/A-23.9220Positive NewsPTGXProtagonist Therapeutics1.5957 of 5 stars$49.87-2.3%$66.10+32.5%+46.7%$3.16B$434.43M66.49120Positive News Related Companies and Tools Related Companies RARE Competitors AAPG Competitors MRUS Competitors ACLX Competitors SWTX Competitors RNA Competitors ACAD Competitors SRRK Competitors VKTX Competitors PTGX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MLYS) was last updated on 7/14/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s biggest move, misreportedThe media and financial pundits are all misreading Trump’s actions. They think Trump wants to make Canada t...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mineralys Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Mineralys Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MLYS Stock Alerts